

https://dspace.org/

TwiceYearly Lenacapavir for HIV Prevention in Men and GenderDiverse Persons

Colleen F Kelley; Maribel Acevedo-Quiñones; Allison L Agwu; Anchalee Avihingsanon; Nkosiphile Ndlovu ...

https://hdl.handle.net/10539/48736
WOS

Downloaded from a DSpace repository. https://dspace.org/

Supplementary Appendix

Supplement to: Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med 2025;392:1261-76. DOI: 10.1056/NEJMoa2411858

This appendix has been provided by the authors to give readers additional information about the work.

Supplementary Appendix

Table of Contents

PURPOSE 2 Study Team……. 3
PURPOSE 2 Study Sites, Investigators, and Key Staff…… 6
Global Community Advisory Group…… 11
Supplementary Methods……... 12
Rationale for the Study Design……. 12
HIV Diagnostic Testing and Case Adjudication……. 12
Figure S1. HIV-Testing Algorithm……. 14
Adherence Counseling and Support……. 14
Site-Specific Recruitment Plans……..... 15
Social Harms Reporting and Support for Participants…….. 15
Excerpts from the PURPOSE 2 Full Statistical Analysis Plan……. 16
Analysis of the Primary Efficacy Endpoint……. 16
Figure S2. A High-Level Screening Schema and Contribution of Participants to the Estimation of the bHIV……... 17
Table S1. Recency Outcome from the RITA…….. 19
Table S2. MDRI and FRR ……..…….…….. 20
Table S3. Summary for Key (Alpha-Controlled) Efficacy Evaluations……. 23
Multiple Comparisons……... 24
Table S4. Testing Sequence of Null Hypotheses…… 24
Alpha Spending for Multiple Analyses (Interim and Primary Analyses)…… 24
Supplementary Results……. 29
Figures……. 30
Figure S3. Time from First Dose to HIV-1 Diagnosis…… 30
Figure S4. Injection-Site Reactions (Nodules, Pain, and Erythema)…….. 31
Tables……... 32
Table S5. HIV Test Results for Participants Adjudicated to Have HIV at Baseline... 32
Table S6. Screening and Baseline Demographics and Clinical Characteristics…….. 34
Table S7. Time at Risk of HIV in the Study and Retention Based on Attending Study Visit and Receiving HIV Testing…….. 38
Table S8. Adherence……... 40
Table S9. Clinical Hold……... 41
Table S10. The Incidence of Laboratory-Diagnosed *N. gonorrhoeae, C. trachomatis*……... 43
Table S11. The Incidence of Syphilis…… 44
Table S12. HIV Test Results in Participants Receiving Lenacapavir Who Were Diagnosed with HIV-1…… 45
Table S13. Grade 3 or Higher Adverse Events……... 46

Table S14. Adverse Events Leading to Premature Study Drug Discontinuation…… 58
Table S15. Grade 3 and 4 Laboratory Abnormalities…….. 60
Table S16. PURPOSE 2 in Comparison with Previous PrEP Trials……... 64
Table S17. Participants in PURPOSE 2 Reflect Global Populations of Cisgender Gay, Bisexual, and Other Men; Transgender Women; Transgender Men; and Gender Nonbinary Individuals Disproportionately Affected by HIV Acquisition and Historically Underrepresented in PrEP Clinical Trials……. 65
References……. 67

PURPOSE 2 Study Team

Principal investigator	Country	Site name
Maribel Acevedo-Quiñones	Puerto Rico	Centro Ararat — San Juan
Allison L. Agwu	United States	Johns Hopkins University School of Medicine
Suvaporn Anugulruengkitt	Thailand	Chulalongkorn University
Anchalee Avihingsanon	Thailand	HIV-NAT, Thai Red Cross AIDS Research Centre and Center of Excellence in Tuberculosis
Joanne Batting	South Africa	Foundation for Professional Development
Jose A. Bazan	United States	The Ohio State University College of Medicine
Paul Benson	United States	Be Well Medical Center
Vladimir Berthaud	United States	Meharry Medical College
Jill Blumenthal	United States	University of California San Diego — Antiviral Research Center
Indira Brar	United States	Henry Ford Hospital
Cynthia Brinson	United States	Central Texas Clinical Research
Carlos Brites	Brazil	Complexo Hospitalar Universitário Professor Edgard Santos
Pedro Cahn	Argentina	Fundación Huésped
Thomas B. Campbell, IV	United States	Colorado Clinical and Translational Sciences Institute (CCTSI)
Valeria D. Cantos	United States	Emory University — Ponce de Leon Center Clinical Research Site HIV/AIDS Clinical Trials Unit
Michelle Cespedes	United States	Mount Sinai Downtown CRS
Ploenchan Chetchotisakd	Thailand	Srinagarind Hospital
Jesse Clark	United States	University of California Los Angeles (UCLA)
Meredith Clement	United States	Louisiana State University Health Sciences Center
Katya Corado	United States	Lundquist Institute for Biomedical Innovation (LA BioMed)
Gonzalo Corral	Argentina	Instituto de Investigaciones Clínicas Mar del Plata
Catherine Creticos	United States	Howard Brown Health Sheridan
Gordon E. Crofoot	United States	Crofoot MD Clinic and Research Center
Edwin DeJesus	United States	Orlando Immunology Center
Ricardo S. Diaz	Brazil	Universidade Federal de São Paulo
Craig Dietz	United States	KC Care Health Center — Midtown
Susanne Doblecki-Lewis	United States	Jackson Memorial Hospital, University of Miami Miller School of Medicine
David F. Dougherty	United States	Baptist Health Lexington
Ian Frank	United States	Penn Medicine — Perelman Center for Advanced Medicine

James W. Galbraith	United States	Open Arms Healthcare Center
Jorge A. Gallardo-Cartagena	Peru	Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos
Aditya Gaur	United States	St. Jude Children's Research Hospital
Beatriz Grinsztejn	Brazil	Fundação Oswaldo Cruz — Instituto Nacional de Infectologia Evandro Chagas
Marcus Guimaraes De Lacerda	Brazil	Fundação de Medicina Tropical Doutor Heitor Vieira Dourado
Michael Guyton-Nunley	United States	Prisma Health Adolescent and Young Adult Medicine
Shawn K. Hassler	United States	Optimus Medical Group/StudyOps
Christine L. Heumann	United States	Bell Flower Clinic
Juan Carlos Hinojosa Boyer	Peru	Asociación Civil Selva Amazónica
Theo Hodge	United States	Washington Health Institute
Moises A. Huaman	United States	University of Cincinnati Health Holmes Hospital
Richard Kaplan	South Africa	Desmond Tutu Health Foundation
Colleen F. Kelley	United States	The Hope Clinic of Emory University
Sasisopin Kiertiburanakul	Thailand	Faculty of Medicine Ramathibodi Hospital
Javier Ricardo Lama Valdivia	Peru	Asociación Civil Impacta Salud y Educación - Barranco CRS
Anthony LaMarca	United States	Therafirst Medical Center
Marcelo H. Losso	Argentina	Hospital General de Agudos José María Ramos Mejía
Christopher Lucasti	United States	South Jersey Infectious Disease
Morakane Alicia Caroline Makwela	South Africa	Setshaba Research Centre
Weerawat Manosuthi	Thailand	Bamrasnaradura Infectious Diseases Institute
Kenneth H. Mayer	United States	Fenway Health Medical Clinic
Eric G. Meissner	United States	Medical University of South Carolina
Ivan Melendez-Rivera	Puerto Rico	Centro Ararat-Ponce
Anthony Mills	United States	Mills Clinical Research
Kathryn Mngadi	South Africa	Aurum Institute — Clinical Research Tembisa
Caryn G. Morse	United States	Wake Forest University Baptist Medical Center
Karam Mounzer	United States	Philadelphia FIGHT Community Health Centers — Jonathan Lax Treatment Center
Nkosiphile Ndlovu	South Africa	Wits Reproductive Health and HIV Institute (Wits RHI)
Richard M. Novak	United States	University of Illinois Medical Center
Onyema Ogbuagu	United States	Yale New Haven Hospital
Alma Minerva Perez Rios	Mexico	Centro De Investigacion Farmaceutica Especializada de Occidente
Nittaya Phanuphak	Thailand	Institute of HIV Research and Innovation — Pribta Tangerine Clinic

Jose Henrique Pilotto	Brazil	Hospital Geral de Nova Iguaçu / AIDS and Molecular Immunology Laboratory / IOC / Fiocruz
Jorge Pinto	Brazil	Universidade Federal de Minas Gerais
Jose Valdez Ramalho Madruga	Brazil	Centro de Referência e Treinamento DST/AIDS-SP
Moti Ramgopal	United States	Midway Immunology and Research Center
Jeffrey S. Reeves	United States	Norton Infectious Diseases Institute
Lina Rosengren-Hovee	United States	UNC Global HIV Prevention and Treatment Clinical Trials Unit
Peter J. Ruane	United States	Ruane Clinical Research Group
Kamla Sanasi-Bhola	United States	Prisma Health Richland Hospital
Breno Santos	Brazil	Hospital Nossa Senhora da Conceição
Patric Schine	United States	Bios Clinical Research
Tanya Schreibman	United States	CAN Community Health — Sarasota
Hyman Scott	United States	San Francisco Department of Public Health
Namrata Shah	United States	Whitman-Walker Health
Peter Shalit	United States	Peter Shalit MD and Associates
Jihad Slim	United States	Saint Michael's Medical Center
LaShonda Y. Spencer	United States	Charles R. Drew University
Khuanchai Supparatpinyo	Thailand	Chiang Mai University — Research Institute for Health Sciences (RIHES)
Javier Valencia	Peru	Asociacion Civil Impacta Salud y Educacion — San Miguel CRS
Cornelius N. Van Dam	United States	Cone Health Regional Center for Infectious Disease
Olivia T. Van Gerwen	United States	University of Alabama at Birmingham
Ricardo Vasconcelos	Brazil	Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Jose Gabriel Vasquez Cerro	Peru	Via Libre
Jennifer Veltman	United States	Loma Linda University Medical Center
Robert Woolard	United States	Centro San Vicente — Pebble Hills Clinic
Kimberly Workowski	United States	Emory University Hospital Midtown
Ashraf Zadshir	United States	Bios Clinical Research
Zwelethu Zwane	South Africa	Aurum Institute — Clinical Research Pretoria